RGI-2001

DRUG3 trials

Sponsors

Regimmune Corporation, Zachariah Michael DeFilipp

Conditions

ALLAMLAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute-graft-versus-host DiseaseBlood Stem Cell Transplant FailureCMMLChemosensitive Hodgkin Lymphoma

Phase 1

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

CompletedNCT01379209

Regimmune CorporationGraft Versus Host Disease

Start: 2011-09-30End: 2017-04-30Updated: 2019-10-23

Haplo Peripheral Blood Sct In GVHD Prevention

CompletedNCT04473911

Zachariah Michael DeFilippAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia, ALL +13

Start: 2020-08-14End: 2024-08-19Updated: 2025-07-20

Phase 2

RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation

CompletedNCT04014790

Regimmune CorporationAcute-graft-versus-host Disease, Graft-versus-host-disease, Graft Vs Host Disease +1

Start: 2019-11-25End: 2023-04-03Updated: 2024-05-28

Related Papers

RGI-2001 for the prophylaxis of acute graft-versus-host disease after allogeneic HCT.

2025-10-01

RGI-2001 Infusion for Prevention of Acute Gvhd after Allogeneic Hematopoietic Cell Transplantation

Blood2022-11-155 citations